STOCK TITAN
  1. Home
  2. News
  3. GENFF

GENFLOW BIOSCIENCES PLC - GENFF STOCK NEWS

Welcome to our dedicated page for GENFLOW BIOSCIENCES PLC news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on GENFLOW BIOSCIENCES PLC stock.

Genflow Biosciences Plc (GENFF) is a biotechnology company leading in longevity research, dedicated to developing therapeutic solutions for age-related diseases. Founded in 2020, Genflow is headquartered in the UK with R&D facilities in Belgium. The company's focus is on pioneering gene therapies to slow down the aging process, aiming to extend healthy lifespans and address the challenges posed by an aging global population. Genflow's flagship product, GF-1002, delivers a centenarian variant of the SIRT6 gene, showing promising preclinical outcomes. In 2025, Genflow will launch clinical trials to test GF-1002's potential in treating MASH, the most common chronic liver disease with no existing effective treatments.

News

Genflow Biosciences PLC Announces Temporary Suspension

Rhea-AI Summary

Genflow Biosciences PLC announces a temporary suspension of listing due to delays in publishing its Annual Financial Report for the financial year ending on December 31, 2023. The delay is not related to the company's financial position. The listing of the company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended from May 1, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Genflow Biosciences PLC Announces Total Voting Rights

Rhea-AI Summary

Genflow Biosciences PLC, a leader in longevity research, disclosed its total voting rights on April 30, 2024. The company's total issued share capital consists of 349,706,618 Ordinary Shares with no shares held in treasury, resulting in the same number of voting rights. Shareholders can use this figure to determine their disclosure obligations under the Financial Conduct Authority's rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Genflow Biosciences PLC Announces Notification of Major Holdings - 1

Rhea-AI Summary
Genflow Biosciences PLC announces notification of major holdings by Mr. Eric Leire, with a total of 35.6% of voting rights attached to shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Genflow Biosciences PLC Announces Successful Placing and Subscription

Rhea-AI Summary
Genflow Biosciences Plc successfully raised £715,000 through a placing and subscription of 57,200,000 new Ordinary Shares. The funds will be used for the development of therapeutic longevity solutions, specifically targeting the potential cure of the liver disease NASH. CEO Dr. Eric Leire personally invested £50,000 in the Placing, showcasing confidence in the company's future. The company's unique approach in longevity research has attracted interest from UK and US institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Genflow Biosciences PLC Announces Notification of Major Holdings

Rhea-AI Summary
Genflow Biosciences PLC announces acquisition or disposal of voting rights by Jonathan Mark Swann, resulting in a 3.03% voting rights position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Genflow Biosciences PLC Announces Publication of a Key European Patent

Rhea-AI Summary
Genflow Biosciences announces the publication of a key European patent in partnership with the University of Rochester, New York, et al., focusing on developing therapeutic solutions for age-related diseases. The patent enhances understanding of age-related diseases by targeting the SIRT6 gene/protein. Genflow's lead drug candidate, GF-1002, aims to treat non-alcoholic steatohepatitis (NASH) patients. The company received positive feedback for clinical trials in Belgium and expects to finalize trial designs in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Rhea-AI Summary
Genflow Biosciences Plc (GENFF) has released its year-end review and strategic priorities for 2024. The company achieved significant milestones in 2023, including expanding its intellectual property portfolio, trading on the OTCQB Venture Market, and receiving positive feedback on clinical trials. In 2024, Genflow aims to broaden its research pipeline, advance clinical development activities, and initiate discussions with regulatory agencies. CEO Dr. Eric Leire expressed confidence in the company's potential for growth and advancement in the field of longevity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024

Rhea-AI Summary
Genflow Biosciences Plc, an emerging leader in longevity research, achieved significant milestones in 2023, including expanding its intellectual property portfolio, trading on the OTCQB Venture Market, and receiving positive feedback on clinical trials for its lead drug candidate. The company's strategic priorities for 2024 include undertaking key IND-enabling development activities, commencing discussions with the EMA, and selecting a CDMO for advancing GMP manufacturing. The CEO, Dr. Eric Leire, expressed optimism for 2024, highlighting the potential benefits of the lead drug candidate, GF-1002, for NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants

Rhea-AI Summary
Genflow Biosciences Plc has announced the initiation of two significant research programs in collaboration with Revatis SA and EXO Biologics, backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. These programs aim to strengthen Genflow's position in the field of longevity research and improve the health and well-being of older adults. The Sarcopenia Research Program with Revatis SA and mRNA Delivery Research with EXO Biologics are generously funded by new grants totaling 1.34 million euros and 1.55 million euros respectively. These initiatives demonstrate Genflow's momentum in leading-edge research and hold the potential to revolutionize therapeutic interventions for age-related conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
News

Genflow Biosciences PLC Announces Two Non-Dilutive Research Grant Awards

Rhea-AI Summary
Genflow Biosciences Plc secures two research grants from Belgium's New Technological Innovation Partnership, one for a sarcopenia research program with Revatis SA and another for mRNA delivery research with EXO Biologics. The grants are part of the Wallonia Recovery Plan by the Walloon Government in Belgium and will be disbursed annually, contingent upon the achievement of specific milestones. The partnership has a budget of 81 million euros, with 60% public funding and 40% private contributions. Genflow's CEO, Dr. Eric Leire, expressed excitement about the new research programs, emphasizing their strategic importance in enhancing the company's research capabilities and contributing to the understanding of age-related conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of GENFLOW BIOSCIENCES PLC (GENFF)?

The current stock price of GENFLOW BIOSCIENCES PLC (GENFF) is $0.0423 as of October 3, 2024.

What is the market cap of GENFLOW BIOSCIENCES PLC (GENFF)?

The market cap of GENFLOW BIOSCIENCES PLC (GENFF) is approximately 14.8M.

When was Genflow Biosciences Plc founded?

Genflow Biosciences Plc was founded in 2020.

Where is Genflow Biosciences Plc headquartered?

Genflow Biosciences Plc is headquartered in the UK.

What is the primary focus of Genflow Biosciences Plc?

Genflow Biosciences Plc is focused on developing therapeutic solutions for age-related diseases through pioneering gene therapies.

What is GF-1002?

GF-1002 is Genflow Biosciences Plc's lead compound that delivers a centenarian variant of the SIRT6 gene, showing promising preclinical results.

What disease does Genflow Biosciences Plc aim to treat with GF-1002?

Genflow Biosciences Plc aims to explore the potential benefits of GF-1002 in treating MASH, the most prevalent chronic liver disease.

What is the research focus of Genflow Biosciences Plc?

Genflow Biosciences Plc is conducting research on exosome-based therapies targeting liver fibrosis and Werner Syndrome, an accelerated aging disease.

What recent grant funding has Genflow Biosciences Plc received?

Genflow Biosciences Plc received a grant from the Government of Wallonia in Belgium for the Exofastrack research program.

When will Genflow Biosciences Plc start its clinical trial for GF-1002?

Genflow Biosciences Plc is scheduled to begin clinical trials for GF-1002 in 2025.

Stock GENFF logo
GENFLOW BIOSCIENCES PLC

OTC:GENFF

GENFF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

GENFF Stock Data

14.79M
164.63M
64.24%
9.15%
Biotechnology
Healthcare
Link
United States of America
London